Targeted gene sequencing and bioinformatics analysis of patients with gallbladder neuroendocrine carcinoma: A case report

Figure 5 PD-L1 and tumor mutation burden. A and B: Targeted gene sequencing revealed no expression of PD-L1 in gallbladder neuroendocrine carcinoma cells; C and D: Buffer solutions and isotype-matched monoclonal antibodies were used as controls to confirm the specificity of primary antibody binding; E: Targeted gene sequencing also helped quantify the tumor mutation burden. TMB: Tumor mutation burden.